Altimmune, Inc. — Director's Dealing 2023

Aug 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2023-08-15

Reporting Person: Drutz David (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-15	Common Stock, par value $0.0001	P	300	$2.875	Acquired	29785	Indirect

Footnotes

F1: Represents Common Stock purchased and immediately transferred to Pacific Biopharma Associates, LLC.

F2: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.